TYRP1 mRNA goes fishing for miRNAs in melanoma

Nature Cell Biology 19, 1311 (2017). doi:10.1038/ncb3637 Authors: Maria S. Soengas &Eva Hernando A variety of non-coding RNAs have been reported as endogenous sponges for cancer-modulating miRNAs. However, miRNA trapping by transcripts with protein-coding functions is less understood. The mRNA of TYRP1 is now found to sequester the tumour suppressor miR-16 on non-canonical miRNA response elements in melanoma, thereby promoting malignant growth.
Source: Nature Cell Biology - Category: Cytology Authors: Tags: News and Views Source Type: research

Related Links:

CONCLUSION Familiarization with these unique presentations of skin cancer in skin of color is imperative to accurate identification and treatment of cutaneous malignancies in these populations and ultimately to improved disease-related outcomes.
Source: Dermatologic Surgery - Category: Dermatology Tags: Review Article Source Type: research
In this study, silymarin nanoemulsion (SN) was used along with air CAP as therapeutic agent ...
Source: Cell Communication and Signaling - Category: Molecular Biology Authors: Tags: Research Source Type: research
L. Shields In contrast to the well-established association between ultraviolet radiation (UVR) exposure and skin cancers, the relationship between UVR and uveal malignant melanoma (UM) remains controversial. To address this controversy, we evaluated the incidence rates of cutaneous malignancies in the eyelids as a proxy for UVR exposure in the ocular region using a population-based cancer registry. Overall, 74,053 cases of eyelid basal cell carcinoma (BCC) and 7890 cases of melanoma over a 26-year period (1982–2007) were analyzed. The incidence of eyelid basal cell carcinoma and uveal melanoma remained stabl...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Emily Roarty Jing Wang Fei Yang Michelle Barton Jeffrey Rosen Sendurai Mani Over the last decade, both early diagnosis and targeted therapy have improved the survival rates of many cancer patients. Most recently, immunotherapy has revolutionized the treatment options for cancers such as melanoma. Unfortunately, a significant portion of cancers (including lung and breast cancers) do not respond to immunotherapy, and many of them develop resistance to chemotherapy. Molecular characterization of non-responsive cancers suggest that an embryonic program known as epithelial-mesenchymal transition (EMT), which is ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Conclusion: The BHDS can be associated with tumors of the skin and kidney. In this case, we noted ocular melanocytosis, malignant choroidal melanoma, and bilateral pinpoint retinal pigment epithelial detachments.
Source: Retinal Cases and Brief Reports - Category: Opthalmology Tags: Case Report Source Type: research
In this study, in vitro and animal models were used to explore the effect of DLN combined with miR‑21 inhibitor on melanoma cells. The data demonstrated that treatment with 5 µl DLN (final concentration of doxorubicin 5 mg/ml) for 72 h effectively inhibited melanoma cell growth (~75% inhibition). The experiments were then divided into five groups: Control group, vector group, DLN group, miR‑21 inhibitor group and miR‑21 inhibitor + DLN group. Compared with the control group, DLN (5 µl) or miR‑21 inhibitor significantly reduced migration and invasion of melanoma cells, promoted apoptosis and arrested cel...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Authors: Olszanski AJ Abstract According to Dr. Anthony J. Olszanski, the most significant updates to the treatment of cutaneous melanoma include the recently published results of MSLT-II, which demonstrated that ultrasound-guided follow-up can be performed rather than a complete lymph node dissection, improving morbidity in patients with sentinel node metastases while not adversely affecting survival. In the adjuvant setting, the PD-1 inhibitors nivolumab and pembrolizumab are now FDA-approved, in addition to dabrafenib and trametinib, for patients with BRAF mutations. PMID: 31117032 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
We present a model in which SLNCR recruits AR to EGR1-bound genomic loci and switches EGR1-mediated transcriptional activation to repression of the tumor suppressor p21Waf1/Cip1. Our data implicate the regulatory triad of SLNCR, AR, and EGR1 in promoting oncogenesis and may help explain why men have a higher incidence of and more rapidly progressive melanomas compared with women.Graphical Abstract
Source: Cell Reports - Category: Cytology Source Type: research
Summer means more time in the sun, which can be good for the bones—all that vitamin D—but bad for the skin. In its annual report on the sunscreens with the least toxic ingredients that are also effective, the Environmental Working Group (EWG) found more than 250 products that measure up. All are free of two ingredients the Food and Drug Administration (FDA) has deemed are not generally safe and effective—PABA and trolamine salicylate—based on research showing these chemicals can contribute to immune system changes and other adverse health effects. The FDA has determined that two other active ingredi...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Cancer environmental toxins sunscreens Source Type: news
(SWOG) At ASCO 2019, SWOG investigators will report on 16 group-led trials, one jointly-led study, and another 12 involving partners. Presentation topics illustrate SWOG's wide-ranging portfolio, with talks and posters on treatment or prevention of bladder, breast, colorectal, lung, pancreatic, prostate, and rare cancers, as well as melanoma and multiple myeloma. SWOG investigators will make a particularly strong showing in symptom control, survivorship, and quality of care trials.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Biology | Cancer | Cancer & Oncology | Cytology | Melanoma | Skin Cancer